Newsletter | June 25, 2021

06.25.21 -- Why A CEO Went From Academia To Biopharma

A Black CEO’s Advice To The Next Generation

As one of the few African American CEOs in corporate America, I am in a unique position to share my experience with the next generation of leaders as we continue to face major challenges around inequity, intolerance, and community cohesion.

From Academia To Industry: How Biopharma Entrepreneurship Became A Calling

While I knew that I wanted to dedicate my life to developing gene therapies to cure human diseases, I could not have predicted that I would leave academia to become an entrepreneur.

Don’t Overlook The Risks Of Innovative Clinical Trials

Advancements in AI and machine learning (ML) for data collection and interpretation could increase the threat of cyberattacks and the malicious hacking of private medical data. As such, sponsors shouldn’t overlook the liability risk of such advancements and the corresponding changes that should be made to business insurance.

Build “Learning Organizations” With Data Science

This is the second in a series of articles about digital and data in the life sciences, looking specifically at what CEOs can do to get more value from them for their companies.

Operationalizing Real-World Evidence (RWE) Teams Across The Enterprise

In recent years, there has been an explosion in the availability of real-world data (RWD) in the healthcare industry. From electronic health records (EHRs) to claims data and nontraditional sources such as wearable technologies, experts estimate that there were likely over 2,314 exabytes of healthcare data produced in 2020 — a notable increase from the 153 exabytes produced in 2013.

Thoughts On Going Public During The Pandemic And The “Muted” Celebration

Marcio Souza, CEO of Praxis Precision Medicines, shares his thoughts on the “muted” celebration from IPOing during the pandemic. Providing additional perspectives are Tom Frohlich (CBO, Chinook Therapeutics), and David Perry (cofounder and chairman of Better Therapeutics).

Special Edition #9: Pitching And Fundraising In The New Norm

Fundraising used to always be done in person. But then COVID-19 hit. From those first virtual pitches that may have been just a little bit “wonky,” biopharma execs have become quite proficient at the process and the platforms. Three biopharma execs share some best practices of the virtual pitch.

June 2021 Digital Edition

Inside you will find more on:

  • Vaxxinity
  • Companies To Watch
  • Industry Research
  • Commercialization Strategies

View the digital edition.

Contribute To Life Science Leader
Article Submission Guidelines

Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director.